Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Verrica Pharmaceuticals (VRCA) EPS (Weighted Average and Diluted) (2021 - 2025)

Verrica Pharmaceuticals has reported EPS (Weighted Average and Diluted) over the past 5 years, most recently at -$0.65 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$0.65 for Q4 2025, up 64.29% from a year ago — trailing twelve months through Dec 2025 was -$0.76 (up 92.99% YoY), and the annual figure for FY2025 was -$1.68, up 88.63%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.65 at Verrica Pharmaceuticals, down from -$0.03 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for VRCA hit a ceiling of $0.02 in Q2 2025 and a floor of -$4.88 in Q3 2024.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$0.37 (2022), compared with a mean of -$0.8.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): surged 100.55% in 2022 and later plummeted 20807.27% in 2023.
  • Verrica Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$0.35 in 2021, then skyrocketed by 60.0% to -$0.14 in 2022, then tumbled by 285.71% to -$0.54 in 2023, then crashed by 237.04% to -$1.82 in 2024, then surged by 64.29% to -$0.65 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.65 (Q4 2025), -$0.03 (Q3 2025), and $0.02 (Q2 2025) per Business Quant data.